Digestive Diseases and Sciences

, Volume 36, Issue 12, pp 1782–1786 | Cite as

Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis

  • B. A. Runyon
  • E. A. Akriviadis
  • F. R. Sattler
  • J. Cohen
Original Articles


Forty-one episodes of ascitic fluid infection were treated with cefotaxime 2 g intravenously every 8 hr, and ascitic fluid and serum were sampled 6, 12, 24, 48, and 96 hr after the first dose of antibiotic. Concentrations of cefotaxime and desacetyl cefotaxime were measured in ascitic fluid and serum by high-performance liquid chromatography. There was essentially 100% penetration of cefotaxime and metabolite from serum into ascitic fluid at all time points. Ascitic fluid was sterilized in 94% of episodes after the first dose of antibiotic. The ascitic fluid concentration of cefotaxime 6 hr after the first dose of antibiotic was greater than 20 times the minimal inhibitory concentration of the drug for 90% of the isolated flora. This rapid ascitic fluid penetration of cefotaxime in high concentration explains the rapid sterilization of ascitic fluid by the drug in the setting of bacterial peritonitis and obviates the need to give a loading dose or intraperitoneal injection.

Key Words

spontaneous bacterial peritonitis cefotaxime ascitic fluid antibiotic concentration 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gerding DN, Hall WH, Schierl EA: Antibiotic concentration in ascitic fluid of patients with ascites and bacterial peritonitis. Ann Intern Med 86:708–713, 1977Google Scholar
  2. 2.
    Felisart J, Rimola A, Arroyo V, Perez-Ayuso RM, Quintero E, Gines P, Rodes J: Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 5:457–462, 1985Google Scholar
  3. 3.
    Moreau L, Durand H, Biclet P: Cefotaxime concentration in ascites. J Antimicrob Chemother 6A:121–122, 1980Google Scholar
  4. 4.
    Galy J, Mantel O: Concentrations de cefotaxime dans les tissues et liquides de l'organisme. Nouv Presse Med 26:565–573, 1981Google Scholar
  5. 5.
    Koda RT, Ko RJ, Nichols S, Akriviadis E, Cohen JL, Runyon B, Sattler FR: Factors influencing the disposition of cefotaxime in various stages of liver disease. Clin Pharmacol Ther 47:154, 1990 (abstract)Google Scholar
  6. 6.
    Lassman HB, Coombes JD: Metabolism of cefotaxime: A review. Diagn Microbiol Infect Dis 2:3S-12S, 1984Google Scholar
  7. 7.
    Runyon BA, Canawati HN, Akriviadis EA: Optimization of ascitic fluid culture technique. Gastroenterology 5:1351–1353, 1988Google Scholar
  8. 8.
    Fabre H, Kok WT: Determination of cephalosporins and decomposition products by liquid chromatography with indirect electrochemical detection. Anal Chem 60:136–141, 1988Google Scholar
  9. 9.
    Runyon BA, Hoefs JC: Culture-negative neutrocytic ascites: A variant of spontaneous bacterial peritonitis. Hepatology 4:1209–1211, 1984Google Scholar
  10. 10.
    Akriviadis EA, Runyon BA: The value of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 98:127–133, 1990Google Scholar
  11. 11.
    Weinstein MP, Iannini PB, Stratton VW, Eickoff TC: Spontaneous bacterial peritonitis: A review of 28 cases with emphasis on survival and factors influencing prognosis. Am J Med 64:592–598, 1978Google Scholar
  12. 12.
    Runyon BA: Spontaneous bacterial peritonitis: An explosion of information. Hepatology 8:171–175, 1988Google Scholar
  13. 13.
    Gill MA, Kern JW: Altered gentamicin distribution in ascitic patients. Am J Hosp Pharm 36:1704–1706, 1979Google Scholar
  14. 14.
    Papadakis MA, Arieff AI: Unpredictability of clinical evaluation of renal function in cirrhosis. Am J Med 82:945–952, 1987Google Scholar
  15. 15.
    Cabrera J, Aroyo V, Ballesta AM, Rimola A, Gual J, Elena M, Rodes J: Aminoglycoside nephrotoxicity in cirrhosis: Value of urinary b2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82:97–105, 1982Google Scholar
  16. 16.
    Moore RD, Smith CR, Lietman PS: Increased risk of renal disfunction due to interaction of liver disease and aminoglycoside. Am J Med 80:1093–1097, 1986Google Scholar

Copyright information

© Plenum Publishing Corporation 1991

Authors and Affiliations

  • B. A. Runyon
    • 1
  • E. A. Akriviadis
    • 1
  • F. R. Sattler
    • 1
  • J. Cohen
    • 1
  1. 1.Departments of Medicine, School of Medicine and School of PharmacyUniversity of Southern CaliforniaLos Angeles

Personalised recommendations